Source
The Globe And Mail
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated profile in ATTR-CM
-Acoramidis further demonstrated early separation of outpatient worsening heart failure seen within 30 days and sustained through Month 30, showing the fastest time to impact of any disease modifying treatment in ATTR-CM
-Acoramidis demonstrated a statistically significant, clinically meaningful 34% reduction in cardiovascular hospitalizations versus tafamidis in a matching-adjusted indirect comparison, with a favorable mortality trend and comparable safety
News Url